Targeting RNA
The recent expansion of the RNA space has resulted in the emergence of many specialised biotechs, particularly in North America and Europe. Investment ranges from $30-70mil across the industry with the hope that biotechs’ activities in achieving proof-of-concept will allow a move into pre-clinical programs.
We’ve collated a list biotechs to watch, as they develop the potential of RNA. Find out who made the list here.
Join the innovative biotechs Anima Biotech, Saverna Therapeutics and Gotham Therapeutics in Frankfurt at the Targeting RNA Congress, 26-27 November, to learn about novel platforms being built for the RNA space. You can view the full agenda here.